|
1) Isner JM. Myocardial gene therapy. Nature. 2002; 415: 234-9
|
|
|
|
2) Hajjar RJ, del Monte F, Matsui T, et al. Prospects for gene therapy for heart failure. Circ Res. 2000; 86: 616-21
|
|
|
|
|
|
3) Pacak CA, Mah CS, Thattaliyath BD, et al. Recombinant adeno-associated virus serotype 9 leads to preferential cardiac transduction in vivo. Circ Res. 2006; 99: e3-9
|
|
|
|
|
|
4) Ikeda Y, Gu Y, Iwanaga Y, et al. Restoration of deficient membrane proteins in the cardiomyo-pathic hamster by in vivo cardiac gene transfer. Circulation. 2002; 105: 502-8
|
|
|
|
|
|
5) Hoshijima M, Ikeda Y, Iwanaga Y, et al. Chronic suppression of heart-failure progression by a pseudophosphorylated mutant of phospholamban via in vivo cardiac rAAV gene delivery. Nat Med. 2002; 8: 864-71
|
|
|
|
|
|
6) Iwanaga Y, Hoshijima M, Gu Y, et al. Chronic phospholamban inhibition prevents progressive cardiac dysfunction and pathological remodeling after infarction in rats. J Clin Invest. 2004; 113: 727-36
|
|
|
|
|
|
7) Iwatate M, Gu Y, Dieterle T, et al. In vivo high-efficiency transcoronary gene delivery and Cre-LoxP gene switching in the adult mouse heart. Gene Ther. 2003; 10: 1814-20
|
|
|
|
|
|
8) Kaye DM, Preovolos A, Marshall T, et al. Percutaneous cardiac recirculation-mediated gene transfer of an inhibitory phospholamban peptide reverses advanced heart failure in large animals. J Am Coll Cardiol. 2007; 50: 253-60
|
|
|
|
|
|
9) Wang Z, Zhu T, Qiao C, et al. Adeno-associated virus serotype 8 efficiently delivers genes to muscle and heart. Nat Biotechnol. 2005; 23: 321-8
|
|
|
|
|
|
10) Gary DJ, Puri N, Won YY. Polymer-based siRNA delivery: perspectives on the fundamental and phenomenological distinctions from polymer-based DNA delivery. J Control Release. 2007; 121: 64-73
|
|
|
|
|
|
11) Kawada T, Nakazawa M, Nakauchi S, et al. Rescue of hereditary form of dilated cardiomyo-pathy by rAAV-mediated somatic gene therapy: amelioration of morphological findings, sarcolemmal permeability, cardiac performances, and the prognosis of TO-2 hamsters. Proc Natl Acad Sci U S A. 2002; 99: 901-6
|
|
|
|
|
|
12) Zhu T, Zhou L, Mori S, et al. Sustained whole-body functional rescue in congestive heart failure and muscular dystrophy hamsters by systemic gene transfer. Circulation. 2005; 112: 2650-9
|
|
|
|
|
|
13) Sun B, Zhang H, Franco LM, et al. Correction of glycogen storage disease type II by an adeno-associated virus vector containing a muscle-specific promoter. Mol Ther. 2005; 11: 889-98
|
|
|
|
|
|
14) Yue Y, Li Z, Harper SQ, et al. Microdystrophin gene therapy of cardiomyopathy restores dystrophin-glycoprotein complex and improves sarcolemma integrity in the mdx mouse heart. Circulation. 2003; 108: 1626-32
|
|
|
|
|
|
15) del Monte F, Hajjar RJ. Targeting calcium cycling proteins in heart failure through gene transfer. J Physiol. 2003; 546: 49-61
|
|
|
|
|
|
16) del Monte F, Harding SE, Dec GW, et al. Targeting phospholamban by gene transfer in human heart failure. Circulation. 2002; 105: 904-7
|
|
|
|
|
|
17) Watanabe A, Arai M, Yamazaki M, et al. Phospholamban ablation by RNA interference increases Ca2＋ uptake into rat cardiac myocyte sarcoplasmic reticulum. J Mol Cell Cardiol. 2004; 37: 691-8
|
|
|
|
|
|
18) Haghighi K, Kolokathis F, Pater L, et al. Human phospholamban null results in lethal dilated cardiomyopathy revealing a critical difference between mouse and human. J Clin Invest. 2003; 111: 869-76
|
|
|
|
|
|
19) Most P, Pleger ST, Volkers M, et al. Cardiac adenoviral S100A1 gene delivery rescues failing myocardium. J Clin Invest. 2004; 114: 1550-63
|
|
|
|
|
|
20) Fischmeister R, Castro LR, Abi-Gerges A, et al. Compartmentation of cyclic nucleotide signaling in the heart: the role of cyclic nucleotide phosphodiesterases. Circ Res. 2006; 99: 816-28
|
|
|
|
|
|
21) Zhang R, Khoo MS, Wu Y, et al. Calmodulin kinase II inhibition protects against structural heart disease. Nat Med. 2005; 11: 409-17
|
|
|
|
|
|
22) Zhang T, Maier LS, Dalton ND, et al. The deltaC isoform of CaMKII is activated in cardiac hypertrophy and induces dilated cardiomyopathy and heart failure. Circ Res. 2003; 92: 912-9
|
|
|
|
|
|
23) Huang B, Wang S, Qin D, et al. Diminished basal phosphorylation level of phospholamban in the postinfarction remodeled rat ventricle: role of beta-adrenergic pathway, G(i) protein, phospho-diesterase, and phosphatases. Circ Res. 1999; 85: 848-55
|
|
|
|
|
|
24) Gupta RC, Mishra S, Rastogi S, et al. Cardiac SR-coupled PP1 activity and expression are increased and inhibitor 1 protein expression is decreased in failing hearts. Am J Physiol Heart Circ Physiol. 2003; 285: H2373-81
|
|
|
|
|
|
25) Zaccolo M, Movsesian MA. cAMP and cGMP signaling cross-talk: role of phosphodiesterases and implications for cardiac pathophysiology. Circ Res. 2007; 100: 1569-78
|
|
|
|
|
|
26) Marx SO, Reiken S, Hisamatsu Y, et al. PKA phosphorylation dissociates FKBP12. 6 from the calcium release channel (ryanodine receptor): defective regulation in failing hearts. Cell. 2000; 101: 365-76
|
|
|
|
|
|
27) Lehnart SE, Wehrens XH, Reiken S, et al. Phosphodiesterase 4D deficiency in the ryano-dine-receptor complex promotes heart failure and arrhythmias. Cell. 2005; 123: 25-35
|
|
|
|
|
|
28) Chen X, Piacentino V, 3rd, Furukawa S, et al. L-type Ca2＋ channel density and regulation are altered in failing human ventricular myocytes and recover after support with mechanical assist devices. Circ Res. 2002; 91: 517-24
|
|
|
|
|
|
29) Wei SK, Ruknudin A, Hanlon SU, et al. Protein kinase A hyperphosphorylation increases basal current but decreases beta-adrenergic respon-siveness of the sarcolemmal Na＋-Ca2＋ exchanger in failing pig myocytes. Circ Res. 2003; 92: 897-903
|
|
|
|
|
|
30) Curran J, Hinton MJ, Rios E, et al. Beta-adrenergic enhancement of sarcoplasmic reticulum calcium leak in cardiac myocytes is mediated by calcium/calmodulin-dependent protein kinase. Circ Res. 2007; 100: 391-8
|
|
|
|
|
|
31) Lai NC, Roth DM, Gao MH, et al. Intracoronary adenovirus encoding adenylyl cyclase VI increases left ventricular function in heart failure. Circulation. 2004; 110: 330-6
|
|
|
|
|
|
32) Yamada M, Ikeda Y, Yano M, et al. Inhibition of protein phosphatase 1 by inhibitor-2 gene delivery ameliorates heart failure progression in genetic cardiomyopathy. FASEB J. 2006; 20: 1197-9
|
|
|
|
|
|
33) Yamaguchi O, Higuchi Y, Hirotani S, et al. Targeted deletion of apoptosis signal-regulating kinase 1 attenuates left ventricular remodeling. Proc Natl Acad Sci U S A. 2003; 100: 15883-8
|
|
|
|
|
|
34) Hikoso S, Ikeda Y, Yamaguchi O, et al. Progres-sion of heart failure was suppressed by inhibition of apoptosis signal-regulating kinase 1 via transcoronary gene transfer. J Am Coll Cardiol. 2007; 50: 453-62
|
|
|
|
|
|
35) Watanabe T, Otsu K, Takeda T, et al. Apoptosis signal-regulating kinase 1 is involved not only in apoptosis but also in non-apoptotic cardiomyo-cyte death. Biochem Biophys Res Commun. 2005; 333: 562-7
|
|
|
|
|
|
36) Bhavsar MD, Amiji MM. Polymeric nano-and microparticle technologies for oral gene delivery. Expert Opin Drug Deliv. 2007; 4: 197-213
|
|
|
|
|
|
37) Nishiyama N, Kataoka K. Current state, achievements, and future prospects of polymeric micelles as nanocarriers for drug and gene delivery. Pharmacol Ther. 2006; 112: 630-48
|
|
|
|
|